Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Merck Sharp & Dohme (Australia)

Overview

The Therapeutic Goods Act 1989 was enacted to establish a national system for regulating therapeutic goods, ensuring their safety, quality, and efficacy. This legislation was introduced to address the need for a comprehensive regulatory framework governing the importation, supply, and manufacturing of therapeutic goods in Australia. The Act is administered by the Therapeutic Goods Administration, a body within the Department of Health, and aims to protect public health by controlling the therapeutic goods available in the Australian market. The policy objective of the Act is to ensure that therapeutic goods available in Australia are of an acceptable standard, thereby minimising health risks to consumers.

Scope and Application

The Therapeutic Goods Act 1989, as amended and administered by the Therapeutic Goods Administration (TGA) within the Commonwealth of Australia, governs the regulation of therapeutic goods, including medicines, medical devices, and blood products. Under sections 14 and 14A of the Act, the TGA can consent to the importation and supply of therapeutic goods that do not fully comply with specified legislative requirements, provided certain conditions are met. This is exemplified in the case of Temozolomide (ASTROMIDE) capsules, where a consent was granted to Merck Sharp & Dohme (Australia) Pty Ltd to import and supply specific batches of products with labels that did not meet the current sponsor/distributor name and address requirements. This consent applies exclusively to the named batches and is subject to conditions such as the use of previously approved labels and the establishment of referral mechanisms for queries or complaints. The Act applies nationally across Australia, with its provisions extending to entities involved in the importation, supply, and distribution of therapeutic goods. However, the Act does not specify exclusions or exemptions in this context, and the scope of its application can be further defined through subordinate instruments such as Therapeutic Goods Orders.

Key Provisions

Under sections 14 and 14A of the Therapeutic Goods Act 1989, the Secretary of the Department of Health has granted consent to Merck Sharp & Dohme (Australia) Pty Ltd for the importation and supply of specific batches of Temozolomide (ASTROMIDE) capsules. These capsules, available in various dosages, have labels that do not comply with certain requirements set out in Therapeutic Goods Order No. 69, particularly in relation to the inclusion of the current sponsor and distributor’s name and address. The consent is narrowly tailored to specific batches of the product and is effective from 27 October 2015. The obligations imposed by this consent include ensuring that the previously approved labels for the former distributor, Willow Pharmaceuticals Pty Ltd, are used. Furthermore, arrangements must be established with the former distributor for the efficient handling of any queries or complaints regarding the products. These complaints and queries are to be promptly referred to Merck Sharp & Dohme (Australia) Pty Ltd, the current sponsor of the products, or to Amneal Pharmaceuticals Pty Ltd, the intended distributor. The Therapeutic Goods Act 1989 also delineates the potential consequences for non-compliance. While specific offences and penalties are not detailed in the notice, breaches of the Act or related regulations can lead to severe civil and criminal penalties. These may include fines, imprisonment, or both, depending on the severity and intent behind the breach. The Therapeutic Goods Act is a stringent piece of legislation designed to protect public health by ensuring that therapeutic goods meet safety, quality, and efficacy standards. Therefore, any failure to comply with its provisions can result in significant legal repercussions for the parties involved.